18F‑alfatide positron emission tomography may predict anti‑angiogenic responses

Liu,Jie; Wang,Dongxu; Meng,Xue; Sun,Xindong; Yuan,Shuanghu; Yu,Jinming

doi:10.3892/or.2018.6692

18F‑alfatide positron emission tomography may predict anti‑angiogenic responses

Authors:
- Jie Liu
- Dongxu Wang
- Xue Meng
- Xindong Sun
- Shuanghu Yuan
- Jinming Yu
View Affiliations

Affiliations: School of Medicine and Life Sciences, University of Jinan‑Shandong Academy of Medical Sciences, Jinan, Shandong 250022, P.R. China, School of Medicine and Life Sciences, University of Jinan‑Shandong Academy of Medical Sciences, Jinan, Shandong 250022, P.R. China, Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong 250117, P.R. China, Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong 250117, P.R. China
Published online on: September 10, 2018 https://doi.org/10.3892/or.2018.6692
Pages: 2896-2905

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As the crucial issue in the development of anti‑angiogenic drugs is how to predict which patients will and will not benefit prior to the initiation of therapy, angiogenic 18F‑alfatide positron emission computed tomography (PET) was assessed in the present study. Lung adenocarcinoma A549 (high angiogenesis) and prostate PC‑3 (low angiogenesis) cell xenografted tumor‑bearing mice underwent 18F‑alfatide PET at baseline and following treatment with either an anti‑angiogenic therapy or vehicle. The evaluation index for the inhibition of tumor growth in the individuals in the treated groups was represented by treatment/control (T/C) ratio (%). Anti‑angiogenic responses were denoted by the changes in 18F‑alfatide uptake in the same animal. The T/C ratio was lower in high‑uptake tumors than in low‑uptake tumors (P=0.001). A significant difference in the tumor volumes between the anti‑angiogenic therapy group and the control group occurred earlier in the A549 model than in the PC‑3 model. 18F‑alfatide uptake decreased more for A549 tumors than for PC‑3 tumors following anti‑angiogenic therapy. In each treatment group, the degree of tumor response to anti‑angiogenic therapy was associated well with the tumor uptake prior to treatment (P<0.05). These results indicated that 18F‑alfatide PET may be a useful molecular imaging tool for individual selection prior to anti‑angiogenic drug therapy.

View Figures

View References

1	Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 29 6 Suppl 16:S15–S18. 2002. View Article : Google Scholar
2	Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995. View Article : Google Scholar : PubMed/NCBI
3	Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
4	Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
5	Jayson GC, Kerbel R, Ellis LM and Harris AL: Antiangiogenic therapy in oncology: Current status and future directions. Lancet. 388:518–529. 2016. View Article : Google Scholar : PubMed/NCBI
6	Kang F, Wang Z, Li G, Wang S, Liu D, Zhang M, Zhao M, Yang W and Wang J: Inter-heterogeneity and intra-heterogeneity of α_vβ₃ in non-small cell lung cancer and small cell lung cancer patients as revealed by ⁶⁸Ga-RGD₂ PET imaging. Eur J Nucl Med Mol Imaging. 44:1520–1528. 2017. View Article : Google Scholar : PubMed/NCBI
7	Niu G and Chen X: Why integrin as a primary target for imaging and therapy. Theranostics. 1:30–47. 2011. View Article : Google Scholar : PubMed/NCBI
8	Danhier F, Le Breton AL and Préat V: RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm. 9:2961–2973. 2012. View Article : Google Scholar : PubMed/NCBI
9	Chen H, Gang N, Hua W and Chen X: Clinical application of radiolabeled RGD peptides for PET imaging of integrin αvβ3. Theranostics. 6:78–92. 2016. View Article : Google Scholar : PubMed/NCBI
10	Gao S, Wu H, Li W, Zhao S, Teng X, Lu H, Hu X, Wang S, Yu J and Yuan S: A pilot study imaging integrin αvβ3 with RGD PET/CT in suspected lung cancer patients. Eur J Nucl Med Mol Imaging. 42:2029–2037. 2015. View Article : Google Scholar : PubMed/NCBI
11	Massoud TF and Gambhir SS: Molecular imaging in living subjects: Seeing fundamental biological processes in a new light. Genes Dev. 17:545–580. 2003. View Article : Google Scholar : PubMed/NCBI
12	Wei YC, Gao Y, Zhang J, Fu Z, Zheng J, Liu N, Hu X, Hou W, Yu J and Yuan S: Stereotactic comparison study of ¹⁸F-alfatide and ¹⁸F-FDG PET imaging in an LLC tumor-bearing C57BL/6 mouse model. Sci Rep. 6:287572016. View Article : Google Scholar : PubMed/NCBI
13	Zhang H, Liu N, Gao S, Hu X, Zhao W, Tao R, Chen Z, Zheng J, Sun X, Xu L, et al: Can a novel ¹⁸F-ALF-NOTA-PRGD2 PET/CT predict the treatment sensitivity of concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma? J Nucl Med. 57:524–529. 2016. View Article : Google Scholar : PubMed/NCBI
14	Luan X, Huang Y, Gao S, Sun X, Wang S, Ma L, Teng X, Lu H, Yu J and Yuan S: ¹⁸F-alfatide PET/CT may predict short-term outcome of concurrent chemoradiotherapy in patients with advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 43:2336–2342. 2016. View Article : Google Scholar : PubMed/NCBI
15	Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y, Li J and Lou L: YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 102:1374–1380. 2011. View Article : Google Scholar : PubMed/NCBI
16	Becker S, Bohn P, Bouyeure-Petit AC, Modzelewski R, Gensanne D, Picquenot JM, Dubray B and Vera P: Bevacizumab enhances efficiency of radiotherapy in a lung adenocarcinoma rodent model: Role of αvβ3 imaging in determining optimal window. Nucl Med Biol. 42:923–930. 2015. View Article : Google Scholar : PubMed/NCBI
17	Wan W, Guo N, Pan D, Yu C, Weng Y, Luo S, Ding H, Xu Y, Wang L, Lang L, et al: First experience of ¹⁸F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med. 54:691–698. 2013. View Article : Google Scholar : PubMed/NCBI
18	Hu M, Xing L, Mu D, Yang W, Yang G, Kong L and Yu J: Hypoxia imaging with 18F-fluoroerythronitroimidazole integrated PET/CT and immunohistochemical studies in non-small cell lung cancer. Clin Nucl Med. 38:591–596. 2013. View Article : Google Scholar : PubMed/NCBI
19	Ji S, Zheng Y, Shao G, Zhou Y and Liu S: Integrin α_vβ₃-targeted radiotracer ^99mTc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin αvβ3 RGD₂ therapy. Theranostics. 3:816–830. 2013. View Article : Google Scholar : PubMed/NCBI
20	Iagaru A, Mosci C, Mittra E, Zaharchuk G, Fischbein N, Harsh G, Li G, Nagpal S, Recht L and Gambhir SS: Glioblastoma multiforme recurrence: An exploratory study of ¹⁸F FPPRGD₂ PET/CT. Radiology. 277:497–506. 2015. View Article : Google Scholar : PubMed/NCBI
21	Minamimoto R, Karam A, Jamali M, Barkhodari A, Gambhir SS, Dorigo O and Iagaru A: Pilot prospective evaluation of ¹⁸F-FPPRGD₂ PET/CT in patients with cervical and ovarian cancer. Eur J Nucl Med Mol Imaging. 43:1047–1055. 2016. View Article : Google Scholar : PubMed/NCBI
22	Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ and Jain RK: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64:3731–3736. 2004. View Article : Google Scholar : PubMed/NCBI
23	Jain RK: Determinants of tumor blood flow: A review. Cancer Res. 48:2641–2658. 1988.PubMed/NCBI
24	Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:841–844. 1993. View Article : Google Scholar : PubMed/NCBI
25	Fukumura D and Jain RK: Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization. Microvasc Res. 74:72–84. 2007. View Article : Google Scholar : PubMed/NCBI
26	Kang F, Wang S, Tian F, Zhao M, Zhang M, Wang Z, Li G, Liu C, Yang W, Li X, et al: Comparing the diagnostic potential of ⁶⁸Ga-Alfatide II and ¹⁸F-FDG in differentiating between non-small cell lung cancer and tuberculosis. J Nucl Med. 57:672–677. 2016. View Article : Google Scholar : PubMed/NCBI
27	Iagaru A, Mosci C, Shen B, Chin FT, Mittra E, Telli ML and Gambhir SS: ¹⁸F-FPPRGD₂ PET/CT: Pilot phase evaluation of breast cancer patients. Radiology. 273:549–559. 2014. View Article : Google Scholar : PubMed/NCBI
28	Zhou Y, Kim YS, Lu X and Liu S: Evaluation of ^99mTc-labeled cyclic RGD dimers: Impact of cyclic RGD peptides and ^99mTc chelates on biological properties. Bioconjug Chem. 23:586–595. 2012. View Article : Google Scholar : PubMed/NCBI
29	Zhou Y, Kim YS, Chakraborty S, Shi J, Gao H and Liu S: ^99mTc-labeled cyclic RGD peptides for noninvasive monitoring of tumor integrin α_Vβ₃ expression. Mol Imaging. 10:386–397. 2011. View Article : Google Scholar : PubMed/NCBI